Published in Br J Clin Pharmacol on April 01, 1977
Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response. Br J Clin Pharmacol (1977) 1.44
The characteristics of the binding of 12-alpha-[3H]-digoxin to the membranes of intact human erythrocytes: relevance to digoxin therapy. Br J Clin Pharmacol (1979) 1.10
Loading dose of digoxin in renal failure. Br J Clin Pharmacol (1980) 0.75
ENZYMATIC BASIS FOR ACTIVE TRANSPORT OF NA+ AND K+ ACROSS CELL MEMBRANE. Physiol Rev (1965) 10.49
Determination of therapeutic and toxic serum digoxin concentrations by radioimmunoassay. N Engl J Med (1969) 6.15
Blood levels of drug at the equilibrium state after multiple dosing. Nature (1965) 3.37
Digoxin metabolism in the elderly. Circulation (1969) 2.56
Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response. Br J Clin Pharmacol (1977) 1.44
Clinical pharmacology of digitalis glycosides. Annu Rev Med (1975) 1.25
Decreased ouabain-sensitive adenosine triphosphatase activity in the erythrocyte membrame of patients with chronic renal disease. Clin Sci Mol Med (1973) 1.21
Effects of digoxin-specific antibodies on accumulation and binding of digoxin by human erythrocytes. J Clin Invest (1973) 1.12
Digoxin pharmacokinetics: role of renal failure in dosage regimen design. Clin Pharmacol Ther (1975) 1.11
Induction of a ouabain-sensitive ATPase defect by uremic plasma. Trans Assoc Am Physicians (1968) 1.02
Effect of age and cardiac glycosides on the activity of adenosine triphosphatase (ATPase) (EC 3.6.1.3) of red cell ghost membranes. Mech Ageing Dev (1975) 0.85
The bioavailability of other digoxin preparations compared with tablets. Postgrad Med J (1974) 0.81
The biological availability of very rapidly dissolving digoxin tablets. Postgrad Med J (1974) 0.81
New method for detecting and quantitating pharmacokinetic drug-drug interactions applied to ethanol-propranolol. Res Commun Chem Pathol Pharmacol (1976) 0.80
Adverse drug reactions: definitions, diagnosis, and management. Lancet (2000) 16.12
Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol (1996) 4.50
Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem (1971) 3.34
Adenosine 3',5'-monophosphate as the intracellular mediator of the action of adrenocorticotropic hormone on the adrenal cortex. J Biol Chem (1967) 3.03
Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. Br J Clin Pharmacol (1975) 2.49
Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomised, placebo-controlled trial. Lancet (2003) 2.47
Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Med Res Methodol (2001) 2.33
Medication errors, worse than a crime. Lancet (2000) 2.24
A prescription for better prescribing. Br J Clin Pharmacol (2006) 2.24
Everest MS: Measurement of digoxin in plasma and its use in diagnosis of digoxin intoxication. Br Med J (1969) 2.08
Abnormal function of potassium channels in platelets of patients with Alzheimer's disease. Lancet (1998) 2.07
Mechanism of the antidepressant action of electroconvulsive therapy. Lancet (1978) 2.03
Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by L-tryptophan or 5-methoxy-N,N-dimethyltryptamine in rats treated with a monoamine oxidase inhibitor. Br J Pharmacol (1971) 1.90
Rare diseases and orphan drugs. Br J Clin Pharmacol (2006) 1.83
Misuse of temazepam. BMJ (1991) 1.82
Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine. Nature (1976) 1.77
Balanced prescribing. Br J Clin Pharmacol (2006) 1.74
Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. Gut (1982) 1.60
Measurement of specific [3H]-ouabain binding to different types of human leucocytes. Br J Clin Pharmacol (1984) 1.56
Electroconvulsive shock increases the behavioural responses of rats to brain 5-hydroxytryptamine accumulation and central nervous system stimulant drugs. Br J Pharmacol (1976) 1.48
Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response. Br J Clin Pharmacol (1977) 1.44
Rational prescribing, appropriate prescribing. Br J Clin Pharmacol (2004) 1.43
Prescribing statins. Br J Clin Pharmacol (2005) 1.42
The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. Br J Clin Pharmacol (1982) 1.40
Iatrogenic chest pain: a case of 5-fluorouracil cardiotoxicity. QJM (1996) 1.39
In defence of polypharmacy. Br J Clin Pharmacol (2004) 1.38
Proceedings: An isolated perfused rat brain--some histological and metabolic features. Clin Sci Mol Med (1974) 1.38
Quipazine: its effects on rat brain 5-hydroxytryptamine metabolism, monoamine oxidase activity and behaviour. Neuropharmacology (1976) 1.35
5-HT1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol (1989) 1.35
Further observations on the effect of repeated electroconvulsive shock on the behavioural responses of rats produced by increases in the functional activity of brain 5-hydroxytryptamine and dopamine. Psychopharmacology (Berl) (1977) 1.35
Plasma noradrenaline and adrenaline concentrations and dopamine-beta-hydroxylase activity in patients with shock due to septicaemia, trauma and haemorrhage. Q J Med (1978) 1.34
Cation transport functions in vitro in patients with untreated essential hypertension: a comparison of erythrocytes and leucocytes. Clin Sci (Lond) (1985) 1.34
Inhibition of 5-hydroxytryptamine-induced human blood platelet aggregation by chlorpromazine and its metabolites. Br J Pharmacol (1975) 1.31
Digitalis intoxication. Clin Sci (Lond) (1983) 1.29
Plagiarism - please don't copy. Br J Clin Pharmacol (2007) 1.29
Responses of isolated human basilar arteries to 5-hydroxytryptamine, noradrenaline, serum, platelets, and erythrocytes. J Neurol Neurosurg Psychiatry (1975) 1.28
The role of brain dopamine in the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats. Neuropharmacology (1974) 1.26
(-)-Propranolol inhibits the behavioural responses of rats to increased 5-hydroxytryptamine in the central nervous system. Nature (1976) 1.26
Biomarkers and surrogate endpoints. Br J Clin Pharmacol (2005) 1.25
Changes in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients receiving digoxin during the early phases of treatment of cardiac failure in regular rhythm and of atrial fibrillation. Br J Clin Pharmacol (1979) 1.23
Clinical pharmacology--providing tools and expertise for translational medicine. Br J Clin Pharmacol (2008) 1.19
A sensitive radioenzymatic assay for adrenaline and noradrenaline in plasma. Br J Clin Pharmacol (1977) 1.17
The epidemiology of carcinoid tumours in England and Scotland. Br J Cancer (1994) 1.15
A comparison of alpha 2-adrenoreceptor binding characteristics of intact human platelets identified by [3H]-yohimbine and [3H]-dihydroergocryptine. J Auton Pharmacol (1983) 1.15
ABC of monitoring drug therapy. Lithium. BMJ (1992) 1.13
The role of brain 5-hydroxytryptamine in the hyperactivity produced in rats by lithium and monoamine oxidase inhibition. Br J Pharmacol (1974) 1.13
ABC of monitoring drug therapy. Making the most of plasma drug concentration measurements. BMJ (1993) 1.13
What is a clinical trial? Br J Clin Pharmacol (2004) 1.13
The effect of diphenylhydantoin on brain 5-hydroxytryptamine metabolism and function. Neuropharmacology (1975) 1.13
Inhibition of 5-hydroxytryptamine-mediated behaviour by the putative 5-HT2 antagonist pirenperone. Neuropharmacology (1983) 1.12
Drug interactions-information, education, and the British National Formulary. Br J Clin Pharmacol (2004) 1.12
Psittacosis masquerading as rheumatic fever. Br Med J (1978) 1.12
The relationship between plasma catecholamines and severity of injury in man. J Trauma (1984) 1.11
Risk perception in drug therapy. Br J Clin Pharmacol (2006) 1.11
Metabolism of an oral tryptophan load. I: Effects of dose and pretreatment with tryptophan. Br J Clin Pharmacol (1980) 1.11
Abnormal regulation of adenosine 3',5'-monophosphate and corticosterone formation in an adrenocortical carcinoma. J Clin Invest (1969) 1.11
Enhanced 5-hydroxytryptamine-mediated behavioural responses in rats following repeated electroconvulsive shock: relevance to the mechanism of the antidepressive effect of electroconvulsive therapy. Psychopharmacology (Berl) (1979) 1.11
Enhancement of specific [3H]ouabain binding and ouabain sensitive 86rubidium influx in intact human lymphocytes by a dialysable factor in human and fetal calf serum. Clin Sci (Lond) (1987) 1.10
Plasma adrenaline and noradrenaline concentrations and dopamine-beta-hydroxylase activity in myocardial infarction with and without cardiogenic shock. Br Heart J (1979) 1.10
Platelet aggregation and chlorpromazine therapy. Br J Clin Pharmacol (1978) 1.10
The characteristics of the binding of 12-alpha-[3H]-digoxin to the membranes of intact human erythrocytes: relevance to digoxin therapy. Br J Clin Pharmacol (1979) 1.10
The use of colour vision measurement in the diagnosis of digoxin toxicity. Q J Med (1980) 1.09
Communicating information about drug safety. BMJ (2006) 1.08
The effects of serum, lithium, ethacrynic acid, and a low external concentration of potassium on specific [3H]-ouabain binding to human lymphocytes after incubation for 3 days. Br J Clin Pharmacol (1986) 1.07
Interaction of azapropazone with phenytoin. Br Med J (Clin Res Ed) (1982) 1.06
The contrasting actions of TRH and cycloheximide in altering the effects of centrally acting drugs: evidence for the non-involvement of dopamine sensitive adenylate cyclase. Neuropharmacology (1976) 1.05
Clinical pharmacokinetics of digoxin 1980. Clin Pharmacokinet (1980) 1.05
Tryptophan hydroxylation in brain. Biochem Biophys Res Commun (1964) 1.04
The metabolism of 14 C-labelled -methyldopa in normal and hypertensive human subjects. Biochem J (1972) 1.04
Evidence for the presence of a vasoactive substance (possibly involved in the aetiology of cerebral arterial spasm) in cerebrospinal fluid from patients with subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry (1976) 1.04
The biosynthesis of 5-hydroxytryptamine in brain. Biochem J (1967) 1.03
Altered distribution of digoxin in renal failure--a cause of digoxin toxicity? Br J Clin Pharmacol (1976) 1.03
Old drugs--new uses. Br J Clin Pharmacol (2007) 1.03
Dietary salt and hypertension: treatment and prevention. Br Med J (Clin Res Ed) (1985) 1.02
The carcinoid syndrome. Am J Cardiol (1968) 1.00
TRH potentiates behavioural changes following increased brain 5-hydroxytryptamine accumulation in rats. Nature (1974) 0.99
Tranylcypromine ('Parnate') overdose: measurement of tranylcypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma. Psychol Med (1979) 0.98
Cation transport abnormalities in vivo in untreated essential hypertension. Clin Sci (Lond) (1986) 0.98
A method for the study of cation transport in vivo: effects of digoxin administration and of chronic renal failure on the disposition of an oral load of rubidium chloride. Clin Sci (Lond) (1984) 0.97
Classifying drug interactions. Br J Clin Pharmacol (2004) 0.97
The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients. Br J Clin Pharmacol (1981) 0.97
Somatostatin, gastrointestinal peptides, and the carcinoid syndrome. Gut (1981) 0.96
Changes in platelet alpha 2-adrenoceptor binding post partum: possible relation to maternity blues. Lancet (1983) 0.96
Prolonged half-life of verapamil in a case of overdose: implications for therapy. Br J Clin Pharmacol (1995) 0.96
Indications for the measurement of plasma digoxin concentrations. Drugs (1983) 0.96